Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$33.41
-2.0%		$38.07
$11.60
▼
$43.73
$5.80B0.311.47 million shs1.72 million shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$106.20
+2.8%		$106.46
$32.22
▼
$117.88
$5.81B1.24570,120 shs732,760 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$66.06
-1.9%		$74.36
$57.74
▼
$90.87
$5.51B0.55786,459 shs792,872 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.30
-0.7%		$25.96
$13.81
▼
$39.89
$1.41B0.314.35 million shs3.25 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%-3.88%-10.45%+0.94%+162.04%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
0.00%-1.76%-3.10%+29.40%+180.21%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
0.00%-4.68%-8.21%-12.08%+13.25%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
0.00%-6.54%-45.79%-41.27%-54.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$33.41
-2.0%		$38.07
$11.60
▼
$43.73
$5.80B0.311.47 million shs1.72 million shs
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$106.20
+2.8%		$106.46
$32.22
▼
$117.88
$5.81B1.24570,120 shs732,760 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$66.06
-1.9%		$74.36
$57.74
▼
$90.87
$5.51B0.55786,459 shs792,872 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.30
-0.7%		$25.96
$13.81
▼
$39.89
$1.41B0.314.35 million shs3.25 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%-3.88%-10.45%+0.94%+162.04%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
0.00%-1.76%-3.10%+29.40%+180.21%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
0.00%-4.68%-8.21%-12.08%+13.25%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
0.00%-6.54%-45.79%-41.27%-54.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.75
Moderate Buy$51.5654.31% Upside
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2.93
Moderate Buy$129.8322.25% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.64
Moderate Buy$98.5549.18% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.52
Moderate Buy$36.63156.16% Upside

Current Analyst Ratings Breakdown

Latest RARE, COGT, DNTH, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$135.00
9/4/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$156.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$28.00 ➝ $19.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$43.00 ➝ $32.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$77.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$58.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$49.00 ➝ $18.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$30.00 ➝ $23.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$83.00 ➝ $37.00
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$2.04M2,846.06N/AN/A$11.41 per share9.31
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.73B3.19$8.77 per share7.53($2.56) per share-25.80
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$673M2.09N/AN/A($0.83) per share-17.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$162.34M-$4.15N/AN/AN/A-10,096.95%-22.53%-21.55%11/5/2026 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$682.64M-$0.58N/A31.012.04-3.80%-362.45%-1.32%11/3/2026 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$575M-$5.84N/AN/AN/A-81.79%-1,024.42%-44.40%11/3/2026 (Estimated)

Latest RARE, COGT, DNTH, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/4/2026Q2 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.8463-$0.90-$0.0537-$0.90$0.30 million$0.76 million
8/4/2026Q2 2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.22-$0.90+$0.32-$0.90$183.08 million$214.00 million
7/30/2026Q2 2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.2363$0.92+$0.6837$0.92$298.63 million$360.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
26.10
26.10
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.39
3.28
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
1.73
1.56

Institutional Ownership

CompanyInstitutional Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%

Insider Ownership

CompanyInsider Ownership
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.02%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.30%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
258173.52 million162.09 millionOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
9254.67 million53.02 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
99183.46 million79.04 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,37198.59 million93.46 millionOptionable

Recent News About These Companies

Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE
September 10 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-106171-shares-of-ultragenyx-pharmaceutical-inc-rare-2026-09-10/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358203/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-rare.html
Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)
September 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RARE/pressreleases/4459694/goldman-sachs-reaffirms-their-hold-rating-on-ultragenyx-pharmaceutical-rare/
Barclays Remains a Buy on Ultragenyx Pharmaceutical (RARE)
September 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RARE/pressreleases/4459164/barclays-remains-a-buy-on-ultragenyx-pharmaceutical-rare/
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.44 Consensus PT from Analysts
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006801
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006001
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Hold" at Royal Bank Of Canada
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006006
The Goldman Sachs Group Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $19.00
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005897
Citigroup Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $28.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005390
HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $25.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005389
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by Wells Fargo & Company
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005388
TD Cowen Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005387
Evercore Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to In-Line
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005383
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to Neutral at Robert W. Baird
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005384
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by JPMorgan Chase & Co.
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005381
Cantor Fitzgerald Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $33.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004278
Jefferies Financial Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004284
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by Bank of America
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004268
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to Market Perform at William Blair
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004274
Canaccord Genuity Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004276
Wedbush Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $23.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004275

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Illustration of an upward-trending stock chart line overlaid on a city skyline of office towers at sunset.
Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
By Nathan Reiff | August 30, 2026
Composite image showing rare earth ore mining, processed metal materials in a factory, and nuclear power plant cooling towers.
3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
By Chris Markoch | September 10, 2026
Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$33.41 -0.67 (-1.97%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$33.78 +0.38 (+1.12%)
As of 09/11/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$106.20 +2.92 (+2.83%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$104.99 -1.21 (-1.14%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$66.06 -1.31 (-1.94%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$66.08 +0.02 (+0.03%)
As of 09/11/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.30 -0.10 (-0.69%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$14.30 0.00 (-0.01%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas